← Back to Clinical Trials
Recruiting NCT07521800

NCT07521800 Remote ECG Monitoring Post TAVI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07521800
Status Recruiting
Phase
Sponsor Medical University of Silesia
Condition TAVI(Transcatheter Aortic Valve Implantation)
Study Type INTERVENTIONAL
Enrollment 250 participants
Start Date 2023-12-01
Primary Completion 2027-02-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Remote ECG monitoringStandard Care (in control arm)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 250 participants in total. It began in 2023-12-01 with a primary completion date of 2027-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The DRAGON TAVI study is a multicenter, prospective, open, randomised trial, which will enrol 250 patients, randomized 1:1 to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and standard care (ie. control group, which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days). The duration of the study is 12 months ± 1 month.

Eligibility Criteria

Inclusion Criteria: * Patient age over 18 years old * Severe aortic stenosis * Moderate or high cardiovascular risk based on current ESC Guidelines "Heart Team" qualification for TAVI * Written informed consent of the patient for participation in the study Exclusion Criteria: * History of atrial fibrillation or atrial flutter * Previously known conduction disturbances\*\* * Presence of: pacemaker, CRT-P, ICD, CRT-D before or after TAVI * Ischaemic stroke, TIA, MI or heart surgery within 1 month before TAVI qualification * Haemorrhagic stroke within 1 year before TAVI qualification * Chronic immunosuppressive therapy * Comorbidities (e.g. drug addiction, alcohol abuse, emotional/mental disorders) which do not allow safe participation in the study

Contact & Investigator

Central Contact

Wojciech Wańha, MD, PhD

✉ wojciech.wanha@gmail.com

📞 504827636

Frequently Asked Questions

Who can join the NCT07521800 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying TAVI(Transcatheter Aortic Valve Implantation). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07521800 currently recruiting?

Yes, NCT07521800 is actively recruiting participants. Contact the research team at wojciech.wanha@gmail.com for enrollment information.

Where is the NCT07521800 trial being conducted?

This trial is being conducted at Turin, Italy, Bialystok, Poland, Katowice, Poland, Katowice, Poland.

Who is sponsoring the NCT07521800 clinical trial?

NCT07521800 is sponsored by Medical University of Silesia. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology